1. Compassionate Use of Letermovir in a 2-Year-Old Immunocompromised Child With Resistant Cytomegalovirus Disease
- Author
-
Julia Natterer, Kristina Murray, Katia Jaton-Ogay, Thomas Mercier, Pascal André, Mattia Rizzi, Maria Pérez Marín, Sandra A. Asner, Thierry Buclin, Onya Opota, Pascal Meylan, Marie-Hélène Perez, Laurent A. Decosterd, and Carole Gengler
- Subjects
Compassionate Use Trials ,Ganciclovir ,medicine.medical_specialty ,Hepatitis, Viral, Human ,medicine.medical_treatment ,Pneumonia, Viral ,Congenital cytomegalovirus infection ,Cytomegalovirus ,Acetates ,Opportunistic Infections ,030230 surgery ,Antiviral Agents ,Polymerase Chain Reaction ,Immunocompromised Host ,03 medical and health sciences ,Letermovir ,Extracorporeal Membrane Oxygenation ,Fatal Outcome ,0302 clinical medicine ,Pharmacokinetics ,medicine ,Extracorporeal membrane oxygenation ,Humans ,Treatment Failure ,030212 general & internal medicine ,Cytomegalovirus disease ,Intensive care medicine ,Dose-Response Relationship, Drug ,medicine.diagnostic_test ,business.industry ,Compassionate Use ,General Medicine ,Viral Load ,medicine.disease ,Infectious Diseases ,Therapeutic drug monitoring ,Child, Preschool ,Cytomegalovirus Infections ,DNA, Viral ,Pediatrics, Perinatology and Child Health ,Quinazolines ,Female ,Drug Monitoring ,business ,medicine.drug - Abstract
Little information on the efficacy and pharmacokinetics of letermovir among immunocompromised children is currently available. We describe here the use of letermovir in a 2-year-old immunocompromised child with ganciclovir-resistant cytomegalovirus disease who required extracorporeal membrane oxygenation. Detailed information on therapeutic-drug-monitoring measures and dosage adjustments for letermovir is provided.
- Published
- 2019
- Full Text
- View/download PDF